These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 28642020)
1. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. Giacalone NJ; Niemierko A; Shipley WU; Efstathiou JA Eur Urol; 2017 Sep; 72(3):e64-e65. PubMed ID: 28642020 [No Abstract] [Full Text] [Related]
2. Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation. Safiri S; Ayubi E Eur Urol; 2017 Sep; 72(3):e63. PubMed ID: 28648368 [No Abstract] [Full Text] [Related]
3. Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11. Goyal NK; Garg M; Goel A Eur Urol; 2012 Aug; 62(2):e41; author reply e42. PubMed ID: 22579049 [No Abstract] [Full Text] [Related]
4. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860 [TBL] [Abstract][Full Text] [Related]
5. Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63:823-9. Eisenberg MS; Leibovich BC; Kim SP Eur Urol; 2013 Oct; 64(4):e84-5. PubMed ID: 23849999 [No Abstract] [Full Text] [Related]
6. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues. Trock BJ; Karnes RJ Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503 [No Abstract] [Full Text] [Related]
7. Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality? Bochner BH; Dalbagni G Eur Urol; 2019 May; 75(5):e138-e139. PubMed ID: 30712972 [No Abstract] [Full Text] [Related]
8. Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18. Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA; Lebret T Eur Urol; 2012 Aug; 62(2):e45-6. PubMed ID: 22579356 [No Abstract] [Full Text] [Related]
9. Reply to Samuel Bishara and Jim Adshead's letter to the editor re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45. Linder BJ; Boorjian SA Eur Urol; 2013 Sep; 64(3):e49-50. PubMed ID: 23787355 [No Abstract] [Full Text] [Related]
10. Re: J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75. Bokarica P; Hrkac A; Gilja I Eur Urol; 2017 Aug; 72(2):e45. PubMed ID: 28279514 [No Abstract] [Full Text] [Related]
11. Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8. Huddart R; Hall E; Lewis R; Porta N; Hussain SA; James ND Eur Urol; 2020 Jun; 77(6):e156-e157. PubMed ID: 32169314 [No Abstract] [Full Text] [Related]
12. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Vila-Reyes H; Joel DeCastro G; McKiernan JM Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798 [No Abstract] [Full Text] [Related]
13. Reply to Michael Froehner, Rainer Koch and Manfred P. Wirth's letter to the editor re: Roman Mayr, Matthias May, Thomas Martini, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012;62:662-70. Mayr R; May M; Fritsche HM Eur Urol; 2013 Jan; 63(1):e10. PubMed ID: 23079054 [No Abstract] [Full Text] [Related]
14. Reply to Vladimir Novotny, Manfred P. Wirth, Michael Froehner's letter to the editor re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol 2014;66:156-163. Roghmann F; May M; Aziz A Eur Urol; 2014 Jul; 66(1):e14. PubMed ID: 24598014 [No Abstract] [Full Text] [Related]
15. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer. Vetterlein MW; Gild P; Fisch M; Rink M Eur Urol; 2020 Aug; 78(2):e77-e78. PubMed ID: 32376138 [No Abstract] [Full Text] [Related]
17. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940 [No Abstract] [Full Text] [Related]
18. Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF Eur Urol; 2019 Apr; 75(4):e98-e99. PubMed ID: 30503180 [No Abstract] [Full Text] [Related]
19. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. Babjuk M; Burger M; Compérat E; Palou J; Rouprêt M; van Rhijn B; Shariat S; Sylvester R; Zigeuner R; Gontero P; Mostafid H Eur Urol; 2017 Jun; 71(6):e173-e174. PubMed ID: 27939074 [No Abstract] [Full Text] [Related]
20. Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol 2015;68:399-405. Nguyen DP; Scherr DS Eur Urol; 2016 Mar; 69(3):e36. PubMed ID: 26187784 [No Abstract] [Full Text] [Related] [Next] [New Search]